Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI eye scan analysis could spot hidden eye disease changes

NCT ID NCT07074041

Knowledge-focused Sponsor: Federico II University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a computer technique called radiomics can help analyze eye scans from people with vitelliform lesions, which are yellow deposits under the retina that can change over time. Researchers looked at 50 participants' OCT images to see if radiomics could distinguish harmless changes from those caused by new blood vessel growth. The goal was to improve diagnosis without invasive tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a new, non-invasive way to help doctors tell apart harmless changes in vitelliform lesions from those needing urgent treatment.
What could go wrong
This is a small, completed study with only 50 participants. The results may not apply to everyone, and radiomics is still an experimental tool not yet ready for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Mar 2022

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study group included all patients, over 18 years old, with a diagnosis of aVLs, evaluated from march 2022 to january 2025.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of acquired vitelliform lesions Exclusion Criteria: * age \< 18 years * axial length higher than 26 mm * the presence of clinically significant cataract * the presence of significant concomitant ocular or systemic diseases (such as diabetic retinopathy, uveitis, glaucoma) * known retinal disorders that could cause vitelliform lesions or retinal fluid (AMD, neovascularization, tractional pathologies, toxic or paraneoplastic syndromes) * inherited dystrophies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired vitelliform lesions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult-onset foveomacular vitelliform dystrophy ornithine carbamoyltransferase deficiency vitelliform macular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitelliform lesions

Contacts and locations

Locations

  • University of Naples, Federico II

    Naples, Italy